0 96

Cited 6 times in

Adjunctive α-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study

Authors
 Kim, Nam Wook  ;  Song, Yul-Mai  ;  Kim, Eosu  ;  Cho, Hyun-Sang  ;  Cheon, Keun-Ah  ;  Kim, Su Jin  ;  Park, Jin Young 
Citation
 International Clinical Psychopharmacology, Vol.31(5) : 265-274, 2016 
Journal Title
 International Clinical Psychopharmacology 
ISSN
 0268-1315 
Issue Date
2016
MeSH
Adult ; Antioxidants/administration & dosage ; Antipsychotic Agents/administration & dosage* ; Antipsychotic Agents/adverse effects* ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Intra-Abdominal Fat/drug effects ; Intra-Abdominal Fat/physiology ; Male ; Middle Aged ; Pilot Projects ; Placebo Effect ; Schizophrenia/diagnosis* ; Schizophrenia/drug therapy* ; Thioctic Acid/administration & dosage* ; Time Factors ; Treatment Outcome ; Weight Gain/drug effects* ; Weight Gain/physiology
Abstract
α-Lipoic acid (ALA) has been reported to be effective in reducing body weight in rodents and obese patients. Our previous open trial showed that ALA may play a role in reducing weight gain in patients with schizophrenia on atypical antipsychotics. The present study evaluated the efficacy of ALA in reducing weight and BMI in patients with schizophrenia who had experienced significant weight gain since taking atypical antipsychotics. In a 12-week, double-blind randomized placebo-controlled study, 22 overweight and clinically stable patients with schizophrenia were randomly assigned to receive ALA or placebo. ALA was administered at 600-1800?mg, as tolerated. Weight, BMI, abdomen fat area measured by computed tomography, and metabolic values were determined. Adverse effects were also assessed to examine safety. Overall, 15 patients completed 12 weeks of treatment. There was significant weight loss and decreased visceral fat levels in the ALA group compared with the placebo group. There were no instances of psychopathologic aggravation or severe ALA-associated adverse effects. ALA was effective in reducing weight and abdominal obesity in patients with schizophrenia who had experienced significant weight gain since beginning an atypical antipsychotic regimen. Moreover, ALA was well tolerated throughout this study. ALA might play an important role as an adjunctive treatment in decreasing obesity in patients who take atypical antipsychotics.
Full Text
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00004850-201609000-00004&LSLINK=80&D=ovft
DOI
10.1097/YIC.0000000000000132
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Psychiatry (정신과학교실) > 1. Journal Papers
Yonsei Authors
김남욱(Kim, Nam Wook)
김어수(Kim, Eosu) ORCID logo https://orcid.org/0000-0001-9472-9465
박진영(Park, Jin Young) ORCID logo https://orcid.org/0000-0002-5351-9549
조현상(Cho, Hyun Sang) ORCID logo https://orcid.org/0000-0003-1019-9941
천근아(Cheon, Keun Ah) ORCID logo https://orcid.org/0000-0001-7113-9286
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/152163
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse